On our screens:Cheap stocks by free cash flow yield
The financials
Bristol Myers Squibb by the numbers
Bristol Myers Squibb (BMY) reported revenue of $13.0B in Q2 2026 (quarter ended Jun 30, 2026), up 5.7% from the same quarter a year earlier. That came with a gross margin of 71% and net income of $3.32B (26% of revenue). For the full year FY2025, revenue was $48.2B (−0.2% year on year) and net income $7.05B. Its largest product in Q2 2026 was Eliquis at $4.48B, 33% of the disclosed total, ahead of Opdivo at 18%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $13.0B | $12.3B | +5.7% |
| Gross profit | $9.25B | $8.90B | +3.9% |
| Operating income | $4.09B | $1.77B | +130% |
| Net income | $3.32B | $1.31B | +153% |
| Diluted EPS | $1.62 | $0.64 | +153% |
| Product | Revenue | Share |
|---|---|---|
| Eliquis | $4.48B | 33% |
| Opdivo | $2.48B | 18% |
| Orencia | $1.03B | 7.5% |
| Yervoy | $769M | 5.6% |
| Reblozyl | $735M | 5.3% |
| Other Growth Brands | $653M | 4.7% |
| Breyanzi | $484M | 3.5% |
| Revlimid | $425M | 3.1% |
| Camzyos | $416M | 3.0% |
| Alliance And Other | $385M | 2.8% |
| Opdualag | $349M | 2.5% |
| Other | $281M | 2.0% |
| Opdivo Ovantig | $261M | 1.9% |
| Pomalyst Imnovid | $204M | 1.5% |
| Other Legacy Brands | $170M | 1.2% |
| Zeposia | $169M | 1.2% |
| Alliance | $104M | 0.8% |
| Sprycel | $88M | 0.6% |
| Sotyktu | $87M | 0.6% |
| Cobenfy | $63M | 0.5% |
| Abraxane | $55M | 0.4% |
| Krazati | $55M | 0.4% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $13.74B (+13%)
Opdivo Ovantig grew +770% year on yearPomalyst Imnovid -71% year on year
Segment Latestquarter on quarteryear on year
- Eliquis$4.48B$4.48BQoQ +8.3%year on year +22%+8.3%+22%
- Opdivo$2.48B$2.48BQoQ +16%year on year -2.9%+16%-2.9%
- Orencia$1.03B$1.03BQoQ +26%year on year +7.4%+26%+7.4%
- Yervoy$769.0M$769.0MQoQ +18%year on year +5.6%+18%+5.6%
- Reblozyl$735.0M$735.0MQoQ +32%year on year +29%+32%+29%
- Other Growth Brands$653.0M$653.0MQoQ +12%year on year +17%+12%+17%
- Breyanzi$484.0M$484.0MQoQ +18%year on year +41%+18%+41%
- Revlimid$425.0M$425.0MQoQ +22%year on year -49%+22%-49%
- Camzyos$416.0M$416.0MQoQ +32%year on year +60%+32%+60%
- Alliance And Other$385.0M$385.0MQoQ +20%year on year +6.9%+20%+6.9%
- Opdualag$349.0M$349.0MQoQ +18%year on year +23%+18%+23%
- Other$281.0M$281.0MQoQ +24%year on year +17%+24%+17%
- Opdivo Ovantig$261.0M$261.0MQoQ +60%year on year +770%+60%+770%
- Pomalyst Imnovid$204.0M$204.0MQoQ -60%year on year -71%-60%-71%
- Other Legacy Brands$170.0M$170.0MQoQ +9.0%year on year -24%+9.0%-24%
- Zeposia$169.0M$169.0MQoQ +43%year on year +13%+43%+13%
- Alliance$104.0M$104.0MQoQ +11%year on year -13%+11%-13%
- Sprycel$88.0M$88.0MQoQ +21%year on year -27%+21%-27%
- Sotyktu$87.0M$87.0MQoQ +26%year on year +24%+26%+24%
- Cobenfy$63.0M$63.0MQoQ +13%year on year +80%+13%+80%
- Abraxane$55.0M$55.0MQoQ +10%year on year -48%+10%-48%
- Krazati$55.0M$55.0MQoQ +10%year on year +15%+10%+15%
- Other Revenue Hedging Activities−$9.0M−$9.0MQoQ -year on year ---
Drug Manufacturers - General
The closest names by size in the same industry